公开(公告)号：US20140249162A1

公开(公告)日：2014-09-04

申请号：US14278955

申请日：2014-05-15

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Jong Chan SON ,  Bong Jin KIM ,  Jae Hak KIM ,  Ill Young LEE ,  Chang Soo YUN ,  Sang Ho LEE ,  Chong Kgo LEE

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: The present invention relates to a pyrrolopyridine derivative represented by the Chemical Formula I, and a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and relates to an antiviral composition including the same as an active ingredient. The compound of the Chemical Formula I has excellent antiviral activity and selectivity for wild type and resistant HIV-1, and thereby is useful as a therapeutic agent for acquired immune deficiency syndrome (AIDS).

Abstract translation: 本发明涉及由化学式I表示的吡咯并吡啶衍生物及其外消旋物或其立体异构体或其药学上可接受的盐，涉及包含其作为活性成分的抗病毒组合物。 化学式I的化合物对野生型和抗性HIV-1具有优异的抗病毒活性和选择性，因此可用作获得性免疫缺陷综合征（AIDS）的治疗剂。

公开(公告)号：US20160297789A1

公开(公告)日：2016-10-13

申请号：US15189771

申请日：2016-06-22

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D

Inventor： Young Sik JUNG ,  Chong Kgo LEE ,  Hae Soo KIM ,  Hee Chun JEONG ,  Pil Ho KIM ,  Soo Bong HAN ,  Jin Soo SHIN ,  Johan NEYTS ,  Hendrik Jan THIBAUT

IPC: C07D307/93 ,  C07D491/048 ,  C07D405/04 ,  C07D409/12 ,  C07D405/12 ,  C07F9/655 ,  C07D417/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  C07D209/94 ,  C07C233/32 ,  C07D407/12

CPC classification number: C07D307/93 ,  C07C233/32 ,  C07D209/94 ,  C07D405/04 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07F9/65517

Abstract: Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Abstract translation: 公开了新颖的茚酮衍生物，其药学上可接受的盐或对映体，其制备方法和用于预防或治疗病毒性疾病的药物组合物，其包含其作为活性成分。 茚酮衍生物对包括柯萨奇，肠反应，脊髓灰质炎和鼻病毒的小核糖核酸病毒具有优异的抑制活性，并且具有低的细胞毒性，因此它们可用作药物组合物的活性成分，用于预防或 治疗包括脊髓灰质炎，麻痹，急性出血性结膜炎，病毒性脑膜炎，手足口病，囊泡病，甲型肝炎，肌炎，心肌炎，胰腺炎，糖尿病，流行性肌痛，脑炎，感冒，呼吸窘迫综合征， 口腔疾病，哮喘，慢性阻塞性肺病，肺炎，鼻窦炎或中耳炎。